Substance Use Disorder Treatment Services

Substance use disorder (SUD) treatment encompasses a structured range of clinical, behavioral, and supportive interventions designed to address dependence on alcohol, opioids, stimulants, and other substances. The field sits at the intersection of mental health medical services and broader specialty medical services, drawing on federally regulated protocols and evidence-based standards. What makes SUD treatment distinct is its layered nature — a single patient may move through detoxification, residential care, outpatient therapy, and long-term medication management over months or years, with different providers and payer rules governing each phase.

Definition and scope

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), classifies substance use disorders on a spectrum from mild to severe, measured by 11 diagnostic criteria including loss of control, social impairment, and physiological dependence. This clinical framing is the foundation on which insurance coverage, treatment authorization, and regulatory context for medical services all rest.

The Substance Abuse and Mental Health Services Administration (SAMHSA) estimates that approximately 48.7 million people aged 12 or older met diagnostic criteria for a substance use disorder in 2022 (SAMHSA 2022 National Survey on Drug Use and Health). Of those, roughly 4 million received any form of specialty treatment in the same year — a gap that shapes much of the policy discussion around access, capacity, and insurance coverage for medical services.

Federal law governing SUD treatment includes 42 CFR Part 2, which imposes stricter confidentiality rules on SUD records than HIPAA's standard framework. The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires that insurance plans offering SUD benefits apply treatment limitations no more restrictive than those applied to comparable medical or surgical benefits.

How it works

SUD treatment is not a single service — it is a clinical continuum. The American Society of Addiction Medicine (ASAM) publishes the widely adopted ASAM Criteria, a multidimensional assessment framework that places patients at one of five broad levels of care based on six assessment dimensions including withdrawal risk, biomedical conditions, and recovery environment.

The five ASAM levels, in ascending intensity:

1. Level 0.5 — Early Intervention: Structured education and brief counseling for patients with emerging risk patterns.
2. Level 1 — Outpatient Services: Fewer than 9 hours of weekly treatment, often individual therapy and medication management.
3. Level 2 — Intensive Outpatient / Partial Hospitalization: Between 9 and 20 hours of structured programming per week, without overnight stays.
4. Level 3 — Residential / Inpatient Services: 24-hour structured living environments with clinical staffing; sub-levels 3.1 through 3.7 describe increasing medical intensity.
5. Level 4 — Medically Managed Intensive Inpatient: Hospital-based, 24-hour physician-managed care for severe withdrawal or co-occurring medical conditions.

Medication-assisted treatment (MAT) — the clinical use of FDA-approved medications such as buprenorphine, methadone, and naltrexone alongside behavioral therapy — spans multiple ASAM levels. The Drug Enforcement Administration (DEA) regulates prescribing authority for Schedule III buprenorphine, while methadone for OUD is dispensed exclusively through DEA-registered Opioid Treatment Programs (OTPs). This how it works framework determines which providers can deliver which treatments in which settings.

Common scenarios

Three clinical presentations illustrate how the treatment continuum operates in practice.

Alcohol Use Disorder with Withdrawal Risk: A patient presenting with a CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol) score above 15 carries risk of severe withdrawal, including seizure. This typically triggers ASAM Level 3.7 (medically monitored withdrawal management) or Level 4 admission, followed by step-down to residential and then outpatient programming. Inpatient vs outpatient medical services distinctions carry direct billing and authorization implications here.

Opioid Use Disorder — Community Stabilization: A patient stabilized on buprenorphine with no acute psychiatric comorbidity typically qualifies for ASAM Level 1 outpatient management. Monthly prescribing visits with a waivered physician, urine drug screening, and 1–2 behavioral health sessions per week represent the standard-of-care package. Telehealth and virtual medical services have meaningfully expanded access for this population since the DEA's 2023 temporary rule permitting audio-only buprenorphine initiation via telemedicine.

Co-occurring Disorder (COD) — Dual Diagnosis: When a patient presents with both SUD and a psychiatric disorder — a combination present in roughly 37% of alcohol use disorder cases and 53% of drug use disorder cases according to SAMHSA — treatment complexity increases substantially. Integrated COD programs, as described in SAMHSA's Treatment Improvement Protocol (TIP) 42, address both conditions simultaneously rather than sequentially.

Decision boundaries

Placement decisions — choosing the right ASAM level — hinge on clinical severity, not patient or family preference. Insurance utilization review processes, governed in part by MHPAEA requirements, assess medical necessity against ASAM Criteria. Payers denying SUD treatment benefits face scrutiny if their criteria diverge from established clinical standards; this has been the basis of federal enforcement actions by the Department of Labor against self-insured plans.

The distinction between detoxification and rehabilitation is consequential for billing: detox is coded as a medical service, while rehabilitation is coded under behavioral health. This split affects medical services billing and coding workflows and can create coverage gaps when a plan's medical and behavioral carve-outs operate independently.

Residential treatment requires prior authorization for medical services from nearly all commercial and Medicaid managed care payers. Authorization periods are typically issued in 7-day or 14-day increments, meaning clinical teams submit continued-stay reviews repeatedly throughout a residential episode. SAMHSA's Behavioral Health Treatment Services Locator, available at findtreatment.gov, functions as the federal reference tool for locating DEA-registered OTPs, residential programs, and outpatient providers by geography and specialty.

The safety boundaries in SUD treatment are defined by withdrawal severity protocols, MAT prescribing regulations, and ASAM level-of-care criteria — three interlocking frameworks that together set the floor for safety context and risk boundaries for medical services across the addiction treatment continuum.